調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020

免疫療法用治療薬の世界市場：単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬

◆タイトル：Immunotherapy Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, Vaccines, (Therapeutic Vaccines and Preventive Vaccines), Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast to 2020
◆商品コード：MAM-PH-3926
◆調査・発行会社：MarketsandMarkets
◆発行日：2015年12月1日
◆ページ数：127
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）

Single User	USD5,650 ⇒換算￥587,600	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥691,600	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥847,600	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、免疫療法用治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、治療薬種類別分析、地域別分析、市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

・イントロダクション
・エグゼクティブサマリー
・市場インサイト
・市場概観/市場動向
・市場シェア分析
・免疫療法用治療薬の世界市場：治療薬種類別分析/市場規模
・免疫療法用治療薬の世界市場：地域別分析/市場規模
・免疫療法用治療薬のアジア市場規模予測
・免疫療法用治療薬のヨーロッパ市場規模予測
・免疫療法用治療薬のアメリカ市場規模予測
・免疫療法用治療薬の世界市場動向
・競争状況
・関連企業分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

The immunotherapy drugs market is expected to grow at a CAGR of 12.8% to reach USD 73,529.2 Million by 2020. The growing focus on cancer therapies with fewer side effects is a key factor driving the growth of the global immunotherapy drugs market. Other factors driving the market include high prevalence rate of lifestyle diseases including cancer, fast track and orphan drug designations expediting the review of drugs. Factors such as high costs of treatment and lesser number of products getting approved are expected to restrict market growth. On the other hand significant growth prospects in the developing economies and high potential of immunotherapy to get approved as first line treatment are the major opportunities in the market.

The immunotherapy drugs market is broadly segmented on the basis of type of drug and geography. The major types of drugs considered include monoclonal antibodies, interferons alpha, interleukins, and vaccines. Among these drugs, monoclonal antibodies are expected to command the largest share while checkpoint Inhibitors is expected to grow at the fastest rate. Both categories of drugs are targeted therapies which act upon the targets that cannot be captured by small-molecule drugs and precisely identify and attack diseased cells, while doing little damage to normal cells.

On the basis of region, the immunotherapy drugs market is segmented into North America, Europe, Asia-Pacific and Rest of the World. (RoW). The North American geographic segment is expected to account for the largest share of immunotherapy drugs market, followed by Europe in 2015. Cancer is one of the highest funded topics of research in North America due to which this segment has gained special focus for research of cancer immunotherapy. Other driving factors include quicker drug approvals by Food and Drug Administration (FDA) and growth in population as well as aging of the population which are also responsible for rapid growth of the immunotherapy drugs market in North America.

Major players operating in the immunotherapy drugs market are Amgen Inc. (U.S.), GlaxoSmithKline Plc. (U.K.), Merck & Co., Inc. (U.S.), Novartis International Ag (Switzerland),and Roche Holding Ag (Switzerland).

【レポートの目次】

1 Introduction (Page No. – 13)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 16)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.2.1 Key Data From Secondary Sources
2.2.2 Key Data From Primary Sources
2.2.2.1 Key Industry Insights
2.2.3 Assumptions for the Study

3 Executive Summary (Page No. – 23)

4 Premium Insights (Page No. – 26)
4.1 Immunotherapy Drugs Market to Grow at A Rapid Rate
4.2 Global Immunotherapy Drugs Market Size
4.3 Geographical Snapshot of the Immunotherapy Drugs Market
4.4 Immunotherapy Drugs Market, By Type of Drug
4.5 Lifecycle Analysis, By Region

5 Market Overview (Page No. – 30)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.4 Drivers
5.4.1 Increasing Adoption of Targeted Therapy Over Traditional Therapy
5.4.2 Reduction in Overall Timeline and Cost for Drug Discovery
5.4.3 High Prevalence Rate of Lifestyle Diseases
5.4.4 Fast Track and Orphan Drug Designations
5.5 Restraints
5.5.1 High Cost of Immunotherapy Treatment
5.5.2 High Attrition Rate in the Product Development Cycle
5.6 Opportunities
5.6.1 Significant Growth Prospects in Developing Countries
5.6.2 Immunotherapy to Replace Chemotherapy as A First-Line Therapy
5.7 Challenges
5.7.1 Patent Expiries of Top-Selling Biologics

6 Cancer Immunotherapy Market- Industry Insights (Page No. – 36)
6.1 Cancer Epidemiology
6.1.1 Estimated Incidence, Mortality, and 5-Year Prevalence: Men (2012)
6.1.2 Estimated Incidence, Mortality, and 5-Year Prevalence: Women
6.1.3 Estimated Incidence, Mortality, and 5-Year Prevalence: Both Sexes (2012)
6.2 Pricing and Reimbursement
6.2.1 U.S.
6.2.2 U.K.
6.2.3 France
6.2.4 Germany
6.2.5 Other European Countries
6.2.6 Japan
6.3 Pipeline
6.3.1 Phase 1
6.3.2 Phase I/II
6.3.3 Phase II
6.3.4 Phase II/III
6.3.5 Phase III
6.3.6 Application Submitted
6.4 Promising Molecules
6.5 Treatment Protocols and Line of Therapies
6.5.1 First Line Therapy
6.5.2 Second Line Therapy
6.5.3 Other Treatments

7 Immunotherapy Drugs Market, By Type of Drugs (Page No. – 63)
7.1 Introduction
7.2 Monoclonal Antibodies
7.3 Interferons
7.4 Interleukins
7.5 Vaccines
7.6 Checkpoint Inhibitors

8 Global Immunotherapy Drugs Market, By Region (Page No. – 76)
8.1 Introduction
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.4 Asia-Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.5 Rest of the World (RoW)

9 Competitive Landscape (Page No. – 94)
9.1 Overview
9.2 Market Share Analysis
9.3 Competitive Situation and Trends
9.3.1 Approvals
9.3.2 Agreements, Partnerships, and Collaborations
9.3.3 Acqusitions

10 Company Profiles (Page No. – 100)
10.1 Introduction
10.2 F. Hoffmann-La Roche Ag
10.2.1 Business Overview
10.2.2 F. Hoffmann-La Roche Ag: Company Snapshot
10.2.3 Products Offered
10.2.4 Recent Developments
10.2.5 MnM View
10.3 Merck & Co., Inc.
10.3.1 Business Overview
10.3.2 Merck & Co., Inc.: Company Snapshot
10.3.3 Products Offered
10.3.4 Recent Developmen
10.3.5 MnM View
10.4 Novartis International Ag
10.4.1 Business Overview
10.4.2 Novartis International Ag: Company Snapshot
10.4.3 Products Offered
10.4.4 Recent Developments
10.4.5 MnM View
10.5 Glaxosmithkline Plc
10.5.1 Business Overview
10.5.2 Glaxosmithkline Plc: Company Snapshot
10.5.3 Product Offered
10.5.4 Recent Developments
10.5.5 MnM View
10.6 Amgen Inc.
10.6.1 Business Overview
10.6.2 Amgen Inc.: Company Snapshot
10.6.3 Products Offered
10.6.4 Recent Developments
10.6.5 MnM View
10.7 Bristol-Myers Squibb
10.7.1 Business Overview
10.7.2 Bristol-Myers Squibb: Company Snapshot
10.7.3 Products Offered
10.7.4 Recent Developments
10.8 ELI Lilly and Company
10.8.1 Business Overview
10.8.2 ELI Lilly and Company: Company Snapshot
10.8.3 Product Offered
10.8.4 Recent Developments
10.9 Celgene Corporation
10.9.1 Business Overview
10.9.2 Celgene Corporation: Company Snapshot
10.9.3 Products Offered
10.9.4 Recent Development
10.10 Seattle Genetics, Inc.
10.10.1 Business Overview
10.10.2 Seattle Genetics, Inc.: Company Snapshot
10.10.3 Product Offered
10.10.4 Recent Developments
10.11 Spectrum Pharmaceuticals, Inc.
10.11.1 Business Overview
10.11.2 Spectrum Phrmaceuticals, Inc.: Company Snapshot
10.11.3 Product Offered
10.11.4 Recent Developments

11 Appendix (Page No. – 121)
11.1 Insights of Industry Experts
11.2 Discussion Guide
11.3 Introducing RT: Real-Time Market Intelligence
11.4 Available Customizations
11.5 Related Reports

List of Tables (37 Tables)

Table 1 Global Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 2 Global Monoclonal Antibody Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 3 North America: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 4 Europe: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 5 Asia-Pacific: Monoclonal Antibody Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 6 Global Interferon Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 7 North America: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 8 Europe: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 9 Asia-Pacific: Interferon Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 10 Global Interleukin Drugs Market Size, 2013-2020 (USD Million)
Table 11 Global Vaccines Market Size, By Region, 2013-2020 (USD Million)
Table 12 Global Vaccines Market Size, By Type, 2013-2020 (USD Million)
Table 13 North America: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 14 Europe: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 15 Asia-Pacific: Vaccines Market Size, By Country, 2013-2020 (USD Million)
Table 16 Global Checkpoint Inhibitor Drugs Market Size, By Region, 2013-2020 (USD Million)
Table 17 North America: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 18 Europe: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 19 Asia-Pacific: Checkpoint Inhibitor Drugs Market Size, By Country, 2013-2020 (USD Million)
Table 20 Global Immunotherapy Drugs Market Size, By Region, 2013–2020 (USD Million)
Table 21 North America: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 22 U.S.: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 23 Canada: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 24 Europe: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 25 Germany: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 26 U.K.: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 27 France: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 28 Italy: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 29 Spain: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 30 APAC: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 31 Japan: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 32 China: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 33 India: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 34 RoW: Immunotherapy Drugs Market Size, By Type of Drug, 2013–2020 (USD Million)
Table 35 Approvals, 2013–2015
Table 36 Agreements, Partnerships, and Collaborations, 2013–2015
Table 37 Acqusitions, 2013-2015

List of Figures (29 Figures)

Figure 1 Research Design: Immunotherapy Drugs Market
Figure 2 Market Size Estimation
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Data Triangulation Methodology
Figure 5 Immunotherapy Drugs Market Snapshot (2015 vs 2020): Checkpoint Inhibitors Will Grow at the Highest Rate in the Next Five Years
Figure 6 Global Immunotherapy Drugs Market, By Type of Drug, 2015
Figure 7 Global Immunotherapy Drugs Market Share, 2015
Figure 8 Changing Demograhics and Focus on Targeted Therapies to Drive Market Growth
Figure 9 Monoclonal Antibodies to Account for the Largest Share of the Market in 2015
Figure 10 APAC to Grow at the Highest Rate During the Forecast Period
Figure 11 Checkpoint Inhibitors Expected to Be the Fastest Growing Segment
Figure 12 North America and APAC Markets Hold Lucrative Growth Opportunities
Figure 13 Market Segmentation
Figure 14 Global Immunotherapy Drugs Market: Drivers, Restraints, Opportunities & Challenges
Figure 15 Monoclonal Antibodies Segment is Expected to Dominate the Market in 2015
Figure 16 Interferon Drugs Market in APAC to Witness Highest Growth From 2015 to 2020
Figure 17 Therapeutic Vaccines to Witness Higher Growth in the Forecast Period
Figure 18 North America to Witness Highest Growth in the Checkpoint Inhibitors Market From 2015 to 2020
Figure 19 Geographic Snapshot (2015): Asia-Pacific Will Be the Fastest-Growing Region By 2020
Figure 20 North America, an Attractive Destination for Monoclonal Antibodies and Checkpoint Inhibitors
Figure 21 North America: Immunotherapy Drugs Market Snapshot
Figure 22 The Checkpoint Inhibitors Segment is the Fastest-Growing Market Segment in the U.S.
Figure 23 The Monoclonal Antibodies Segment to Dominate the Immunotherapy Drugs Market in Europe During the Forecast Period
Figure 24 APAC: Immunotherapy Drugs Market Snapshot
Figure 25 The Increasing Number of Key Market Players Focusing on Latin American Countries is Driving the Immunotherapy Drugs Market in the RoW Region
Figure 26 Companies Adopted New Product Launches and Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 27 Global Immunotherapy Drugs Market Share Analysis, By Key Player, 2014
Figure 28 Battle for Market Share: Approvals Was the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 29 Geographic Revenue Mix of the Top Four Market Players

【レポートのキーワード】

免疫療法用治療薬、単クローン抗体、インターフェロンα、インターロイキン、免疫ワクチン、治療ワクチン、予防ワクチン、免疫チェックポイント阻害薬、医薬品

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[免疫療法用治療薬の世界市場：単クローン抗体、インターフェロンα、インターロイキン、ワクチン、チェックポイント阻害薬]についてメールでお問い合わせはこちら

◆関連調査資料◆

動物向け疼痛治療の世界市場予測（～2023年）
MD6197 / MarketsandMarkets / 2018年4月20日 / 当調査レポートでは、動物向け疼痛治療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品（薬剤、デバイス）別分析、用途別分析、動物種類別分析、販売チャネル別分析、動物向け疼痛治療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...“Global veterinary pain management market projected to grow at a CAGR of 8.0%”The global veterinary pain management market is projected to reach USD 1.66 billion by 2023 from USD 1.13 billion in 2018, at a CAGR of 8.0% during the forecast period. Factors such as growth in companion animal adoption, increasing number of veterinary practitioners and their rising income levels in developed economies, growing prevalence of animal diseases causing pain and inflammation, and rising adoption of pet insurance with growing animal health expenditure are expected to drive the growth of the market. However, increasing pet care cost may restrain market...

抗凝固療法の米国市場予測（～2022年）
MD-5704 / MarketsandMarkets / 2017年11月3日 / ...“The US anticoagulation therapy market projected to grow at a CAGR of 8.5%.”The US anticoagulation therapy market is projected to reach USD 27.83 billion by 2022 from an estimated USD 18.49 billion in 2017, at a CAGR of 8.5%. The US anticoagulation therapy market is segmented into products (anticoagulation drugs, PT/INR testing devices) and anticoagulation clinics. The growth of the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand,...

再生医療の世界市場予測（～2021年）：細胞治療、組織工学、免疫治療、遺伝子治療
MAM--BT-4419 / MarketsandMarkets / 2017年2月10日 / 当調査レポートでは、再生医療の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、治療別分析、製品別分析、用途別分析、地域別分析、再生医療の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...“Regenerative Medicine Market by Therapy (Cell Therapy, Tissue Engineering, Immunotherapy, Gene Therapy), By Product (Cell-Based, Acellular), By Applications (Orthopedic & Musculoskeletal Disorders, Dermatology, Oncology, Cardiology)-Forecast To 2021” The global Regenerative medicine market is expected to reach USD 38.70 billion by 2021 from USD 13.41 billion in 2016 at a CAGR of 23.6% from 2016 to 2021 The major factor driving the growth of regenerative medicine market, are government and private funding to support the development of regenerative medicine, rising prevalence of chronic diseases and genetic disorders, increase in global healthcare expenditure, and rapid growth in the aging population. The global...

米国の不眠症治療市場予測（～2021）：非薬理学的療法別（認知行動療法、催眠療法）、処方せん睡眠薬別（ベンゾジアゼピン、非ベンゾジアゼピン（ザレプロン）、オレキシン遮断薬,）、一般用治療別（抗ヒスタミン剤、メラトニン、ワレリアナ根））
MAM-MD-4947 / MarketsandMarkets / 2017年1月25日 / ...The U.S. insomnia market is projected to reach USD 4.24 billion by 2021 from USD 3.38 billion in 2016, growing at a CAGR of 4.6% from 2016 to 2021. In 2016, the cognitive behavioural therapy for insomnia (CBTI) segment is expected to account for the largest share of the market. The other alternative therapies include exercise/yoga, acupuncture, biofeedback, bright light therapy, music therapy, and aroma therapy. In 2016, the prescription sleep aids segment is expected to account for the largest share of the U.S. insomnia pharmacological treatment market. The launch of Belsomra (Merck & Co., Inc) in 2014 in the...

免疫療法治療薬の世界市場予測（～2021）：薬種類別（成人用ワクチン、チェックポイント阻害剤、インターフェロンアルファ）、治療分野別、需要先別、地域別
MAM-PH-3926 / MarketsandMarkets / 2017年1月6日 / 当調査レポートでは、免疫療法治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、薬種類別分析、治療分野別分析、需要先別分析、地域別分析、免疫療法治療薬の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global immunotherapy drugs market is projected to reach USD 201.52 Billion by 2021 from USD 108.41 Billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. Increasing adoption of targeted therapies with fewer side effects, quicker drug approval processes, and high prevalence rate of lifestyle diseases are major growth drivers of this market. On the other hand, the high cost of immunotherapy treatment, and high attrition rate in the product development cycle are the major factors hindering the growth of the market. However, rising opportunities in the emerging markets, and immunotherapy as...

がん免疫療法の世界市場予測（～2021年）：モノクローナル抗体、がんワクチン、免疫チェックポイント阻害療、免疫調節薬
MAM-BT-4576 / MarketsandMarkets / 2016年9月15日 / 当調査レポートでは、がん免疫療法の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、産業動向、市場シェア分析、種類別分析、用途別分析、需要先別分析、地域別分析、がん免疫療法の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global cancer immunotherapy market is expected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion in 2016, at a CAGR of 14.0% during the forecast period. Market growth can be attributed to the increasing incidence of cancer, rising demand for therapies with minimal adverse effects, increase in adoption of immunotherapy over other treatment options, and enhanced drug development process. However, stringent regulatory policies and the highly consolidated market which may create an obstacle for the entry of small players are the major factors restraining the growth of this market. The cancer immunotherapy market has been segmented on...

ペプチドホルモンの世界市場及びパイプライン分析
KUICK504223 / KuicK Research / 2015年4月 / 当調査レポートでは、ペプチドホルモンの世界市場について調査・分析し、以下の構成でお届けいたします。・ペプチドホルモンの概要・ペプチドホルモン治療の仕組み・ペプチドホルモンの世界市場概要・ペプチドホルモンの世界市場動態・ペプチドホルモンの世界市場展望・ペプチドホルモンの開発パイプライン（治験）動向・ペプチドホルモンの上市品分析・停止・中止されたペプチドホルモン・主要企業分析...Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could be observed in their molecular structure, chemical nature, functionality, site of secretion and action. Among hormones, peptide hormones form an important category consisting of short amino acid chains of varying sizes. They are secreted in miniscule quantities but their effect...

癌細胞増殖阻害剤の世界市場：チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬
KUICK504221 / KuicK Research / 2015年4月 / 当調査レポートでは、癌細胞増殖阻害剤の世界市場について調査・分析し、以下の構成でお届けいたします。・癌細胞増殖阻害剤の概要・癌細胞増殖阻害剤治療の仕組み・癌細胞増殖阻害剤の世界市場概要・癌細胞増殖阻害剤の世界市場動態・癌細胞増殖阻害剤の世界市場展望・チロシンキナーゼ阻害薬の開発パイプライン（治験）動向・HDAC阻害薬の開発パイプライン（治験）動向・MTORタンパク質阻害薬の開発パイプライン（治験）動向・PI3K阻害薬の開発パイプライン（治験）動向...Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are...

インターフェロンの世界市場及びパイプライン分析
KUICK504222 / KuicK Research / 2015年4月 / 当調査レポートでは、インターフェロンの世界市場について調査・分析し、以下の構成でお届けいたします。・インターフェロンの概要・インターフェロン治療の仕組み・インターフェロンの世界市場概要・インターフェロンの世界市場動態・インターフェロンの世界市場展望・インターフェロンの開発パイプライン（治験）動向・インターフェロンの上市品分析・停止・中止されたインターフェロン・主要企業分析...Interferons are small, low molecular weight proteins of varying sizes induced during attack by infectious agents like viruses. Investigators have found that they are highly variable in nature and have several subtypes due to which misunderstanding is easily created. Furthermore, they have synergistic effect in which interferons belonging to different classes have same effect on immune system due to sharing of common pathways. These facts gave emphasis on the development of classification system to organize, recognize, associate relationship and differentiate interferons from each other. Moreover, advent of genome sciences is allowing the investigators to look deeper into the DNA sequences...

がん分子標的治療の世界市場及びインサイト
KUICK504095 / KuicK Research / 2015年4月 / 当調査レポートでは、がん分子標的治療の世界市場について調査・分析し、がん分子標的治療のニーズ、がん分子標的治療の仕組み、ナノメディシンの世界市場概要、市場の動態、市場展望、がん分子標的モノクローナル抗体のパイプライン動向、がんワクチンのパイプライン動向、原癌遺伝子タンパク質のパイプライン動向、チロシンキナーゼのパイプライン動向、上市品分析、主要企業分析等の情報をお届けいたします。...Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆